Josh is a biotech and startup executive with over 10 years of experience in the industry. He served in roles of increasing responsibility at Athira Pharma, Inc. (Nasdaq: ATHA) from 2015 to July 2023 supporting business development, corporate communications, medical affairs, product commercialization, and corporate financing from 2015 through to its IPO in September 2020; his latest appointment with Athira was Vice President of Corporate Development and External Affairs. Josh is also Founder and Principal of S-Phase Ventures, LLC, a boutique strategy, operations and business development consultancy for start-ups, venture funds, and non-profit organizations since 2015. In addition, he has served as an advisor to Bellevue Capital Management (BCM) since March 2015. In June 2018, he became a Consultant at BCM, and in August 2020, he became a Partner at BCM. Josh is the co-founder of Numiera Therapeutics, having taken an active role in the company from January to June 2024. After leaving Numiera Therapeutics, he moved into a new role as Chief Business Development Officer at the Swiss company Landmark BioVentures, where he continues to support startup founders in the life sciences. 

 

Josh earned a BS in Chemistry from Oregon State University (2004). He then earned an MBA (2011) and PhD in Molecular and Cellular Biology (2012) from the University of Washington.